News

April 6, 2018

Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA, Pa. and OXFORD, U.K. — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the upcoming AACR meeting at McCormick Place in Chicago, Illinois.

Session, date, time, and location (for both posters):
•Session Category (Title): Clinical Research (Adoptive Cell Therapy 2)
•Date: Monday Apr 16, 2018
•Time: 1:00 PM – 5:00 PM (CDT)
•Location: McCormick Place South, Exhibit Hall A, Poster Section 24

Poster 1 – MAGE-A4
•Title: Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4
•Poster Board Number: 21
•Permanent Abstract Number: 2562

Poster 2 – MAGE-A10
•Title: Selection of affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE‑A10
•Poster Board Number: 23
•Permanent Abstract Number: 2564

Adaptimmune will also have a booth (#3700) in the Exhibit Hall.

Read More

Back to News